Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xilio Therapeutics ( (XLO) ) has provided an announcement.
On January 8, 2026, Xilio Therapeutics reported a series of corporate and pipeline updates, including the receipt of $35.8 million in gross proceeds in the fourth quarter of 2025 from the exercise of Series B warrants, which extended its estimated cash runway into the second quarter of 2027 and brought preliminary year-end 2025 cash and cash equivalents to about $137.5 million. The company also achieved a development milestone in its masked antibody-based immunotherapy program under its AbbVie collaboration, nominated a development candidate for a wholly owned masked T cell engager targeting CLDN18.2—relevant for gastric, pancreatic, esophageal and lung cancers—and laid out a roadmap of key clinical and regulatory milestones through 2027, including an IND filing and initial Phase 1 data for XTX501, candidate nomination for a STEAP1 program, and advancing at least two masked T cell engager programs into IND-enabling studies. Governance changes were highlighted with the appointment of longtime director and experienced biotech finance executive Sara M. Bonstein as chair of the board following the January 6, 2026 retirement of former chair Paul Clancy, a transition presented as orderly and non-contentious that is expected to reinforce financial and strategic oversight as Xilio seeks to translate its masking platform into value-generating clinical assets and partnership-driven growth.
The most recent analyst rating on (XLO) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
The score is primarily held back by weak financial performance (large losses and negative equity) despite strong revenue growth and improving cash burn. Technical indicators also point to weak momentum. A positive offset is the extended cash runway into Q2 2027 from recent financing activity, but valuation signals remain limited due to the negative P/E and no dividend yield provided.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics, Inc., based in Waltham, Mass., is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies designed to localize anti-tumor activity within the tumor microenvironment and reduce systemic side effects. Leveraging proprietary masking technology, the company is advancing a pipeline that includes masked bispecific PD-1/IL-2 candidates, masked T cell engagers and tumor-activated I-O molecules, targeting a range of solid tumors and supported by strategic collaborations with partners such as Gilead Sciences and AbbVie.
Average Trading Volume: 622,122
Technical Sentiment Signal: Sell
Current Market Cap: $36.49M
For an in-depth examination of XLO stock, go to TipRanks’ Overview page.